La description
I am looking for a distributor in the
field of intervention oncology
products.
Â
Microspheres
Suzhou Haowei Medical Technology Co., Ltd specializes in the
technological innovation of "Drug-Device Combined Product"
technique, aiming to help TACE treatment fulfil clinical unmet
needs through contin- uous research and development and innovation.
A series of innovative products such as drug-eluting microspheres,
resorbable microspheres, radioactive microspheres, balloon occluded
microcatheters and steerable microcatheters developed by the
company have gradually entered the stage of commercial- ization.
PRODUCT
ADVANTAGES
UNIFORM PARTICLE SIZE
1- Precise drug delivery and vascular embolization for different
clinical scenarios, such as emboli- zation of hypervascularized
tumors including hepatoma, and peripheral arteriovenous malfor-
mations.
2- Precise calibrated microspheres (CV controlled within 5%-10%) as
small as 70µm show greater distal penetration and more effective
embolization than larger microspheres without influencing patient
safety [1,2].
3- Study demonstrated that smaller size beads doxorubicin DEBs are
superior to larger ones in terms of achieving a tumor response and
have shown their therapeutic efficacy as a bridge to liver
transplantation [3,4].
4- The use of smaller bead sizes may result in improved tumor
penetration resulting in more dura- ble treatment response [5] have
further shown the use of 40 µm beads to be safe [6], even with
concurrent systemic chemotherapy.
Â
EFFICIENT &
EFFICACY
1- Ready-for-use, no need to reconstitution.
2- Excellent effect of embolization.
3- DEB-TACE is effective and safe for the treatment of HCC, and
interventions with small-caliber DEBs (<100 µm) is recommended.
TACE treatment with small-caliber DEBs (<100 µm) is indicated
for super-selective embolization of feeding arteries in order to
prevent major complications [7].
4- DEB-TACE is associated with a better objective response, disease
control, and lower all-cause mortality with severe complications
compared to C-TACE treatment [8].
5- Small particle DEBIRI using 40 and 75 µm drug-eluting beads is
safe and provides survival benefits com- parable to larger bead
sizes [9].
6- This recent meta-analysis shows that DEB-TACE provides
significantly better tumor response compared with conventional
TACE. One-year and 2-year survival are better with DEB-TACE. In
addition, DEB-TACE is as safe as conventional TACE [10].
7- The meta-analysis using a fixed-effects model showed
significantly better objective tumor response rate for DEB-TACE
compared with conventional TACE (OR = 1.92, 95% CI [1.34, 2.77]; P
= 0.0004), with a relative risk difference of 0.15 [0.07, 0.24] (P
= 0.0003) [10].
Â
| Pays: |
China |
| N ° de modèle: |
-
|
| Prix FOB: |
(Negotiable)
Obtenir le dernier prix
|
| Localité: |
China |
| Prix de commande minimale: |
- |
| Commande minimale: |
300 Unit |
| Packaging Detail: |
we have 1ml:7ml and 2ml:6ml per vial, 1 vial per box, 10 boxes per carton |
| Heure de livraison: |
4-6 weeks depends on quantity |
| Capacité de Fournir: |
10000 Unit per Year |
| Payment Type: |
T/T |
| Groupe de produits : |
- |
